Particle.news

JAMA Study Links New York Medical Cannabis Program to Reduced Opioid Use

An 18‑month patient‑level analysis documented sustained declines in prescribed morphine‑equivalent doses among chronic pain patients.

Overview

  • Researchers at Albert Einstein College of Medicine and Montefiore tracked 204 adults newly certified for New York’s Medical Cannabis Program between September 2018 and July 2023 using state prescription records.
  • Average daily opioid dose fell from 73.3 mg to 57 mg morphine‑equivalent over 18 months, a 22% reduction.
  • In months when participants received a 30‑day cannabis supply, their opioid use was 3.5 mg morphine‑equivalent per day lower than months without cannabis.
  • Authors say the findings support a pharmacist‑supervised, medicalized model for dispensing cannabis in pain management.
  • The observational study, published in JAMA Internal Medicine, provides patient‑level evidence but does not establish causality or broad generalizability.